Müller-Wieland, Dirk
Leiter, Lawrence A.
Cariou, Bertrand
Letierce, Alexia
Colhoun, Helen M.
Del Prato, Stefano
Henry, Robert R.
Tinahones, Francisco J.
Aurand, Lisa
Maroni, Jaman
Ray, Kausik K.
Bujas-Bobanovic, Maja
Clinical trials referenced in this document:
Documents that mention this clinical trial
Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk
https://doi.org/10.1186/s12933-017-0552-4
Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies
https://doi.org/10.1186/s12933-019-0951-9
Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol
https://doi.org/10.1186/s12933-020-0991-1
Funding for this research was provided by:
Sanofi
Regeneron Pharmaceuticals, Inc.
Article History
Received: 9 March 2017
Accepted: 15 May 2017
First Online: 25 May 2017